Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Fu, Rong  [Clear All Filters]
Journal Article
Sheng N, Fu R, Zhou C, Li Y, Fan Y, Wang J, Nan X. SOX9 promotes stemness in the CAL27 cell line of tongue squamous cell carcinoma. Cell Biochem Funct. 2024;42(3):e4000.
Liu Z, Jia Y, Guo Y, Wang H, Fu R. Role of EZH2 in Bone Marrow Mesenchymal Stem Cells and Immune-Cancer Interactions. Crit Rev Oncol Hematol. 2021:103547.
Sun H, Liu A, Liu L, Wang W, Cai Z, Yan H, Chen L, Gao G, Wang F, Liao A, et al. Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China. BMC Cancer. 2023;23(1):930.
de Latour RPeffault, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994-1008.
Wang H, Liu H, Li L, Chen Y, Liu Z, Li L, Ding S, Ding K, Fu R. Long noncoding RNA FAM157C contributes to clonal proliferation in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2023.
An Z-Y, Wu Y-J, Hou Y, Mei H, Nong W-X, Li W-Q, Zhou H, Feng R, Shen J-P, Peng J, et al. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Sci Bull (Beijing). 2023.
Fu R, Ding S-X, Liu YI, Li L-J, Liu H, Wang H-L, Zhang T, Shao Z-H. Expression and function of hematopoiesis-stimulating factor receptors on the GPI(-) and GPI(+) hematopoietic stem cells of patients with paroxysmal nocturnal hemoglobinuria/aplastic anemia syndrome. Exp Ther Med. 2016;11(5):1668-1672.
Zhang W, Shao Z, Fu R, Wang H, Li L, Yue L. Effect of DLK1 on tumorigenesis in CD34(+)CD38(-) bone marrow cells in myelodysplastic syndromes. Oncol Lett. 2013;6(1):203-206.
Liu Z, Mi F, Han M, Tian M, Deng L, Meng N, Luo J, Fu R. Bone marrow-derived mesenchymal stem cells inhibit CD8 T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. Clin Exp Immunol. 2021.